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ABSTRACT 
Objective: Hyperphosphatemia is significantly associated with increased mortality among end-stage renal disease (ESRD) patients on hemodialysis. 
There is a paucity of data on hyperphosphatemia in ESRD patients of the multiethnic population of United Arab Emirates (UAE). The study aimed to 
investigate the prevalence and characteristics of hyperphosphatemia in ESRD patients of the multiethnic population of UAE undergoing 
maintenance hemodialysis.  
Methods: Adults ESRD patients undergoing maintenance hemodialysis for more than six months at the study site were included. Demographic, 
clinical and biological data of the patients were collected. Patient characteristics were compared as per the serum phosphate level, between patients 
with or without hyperphosphatemia. Univariate and multivariate logistic regression analyses were carried out to identify the predictors of 
hyperphosphatemia.  
Results: Hyperphosphatemia was present in 73.8% of the study population, while 31.3% presented with the high calcium-phosphate product. 
Univariate logistic analysis revealed that hyperphosphatemia was inversely correlated with age, haemoglobin, serum calcium, and hypertensive 
nephropathy as the cause of renal disease, and positively correlated with female gender, expatriate status, body mass index (BMI), a higher number 
of comorbidities, calcium-phosphate product and parathyroid hormone (PTH). Multivariate logistic regression model revealed that only age, BMI, 
haemoglobin and PTH independently correlated with hyperphosphatemia.  
Conclusion: We report a high prevalence of hyperphosphatemia in multiethnic study population undergoing maintenance hemodialysis at a 
secondary care hospital in UAE. In this study population, only age, BMI, hemoglobin and PTH were identified as independent predictors of 
hyperphosphatemia. 
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Hyperphosphatemia in end-stage renal disease (ESRD) is a common 
and serious biochemical abnormality linked to vascular calcification, 
renal osteodystrophy and secondary hyperparathyroidism [1-4]. 
The abnormality is significantly associated with increased mortality 
among ESRD patients on hemodialysis [5-7]. Studies have also 
shown a strong association of hyperphosphatemia with 
cardiovascular morbidity and mortality in ESRD patients [8-10]. 
Consequently, adequate control of serum phosphate is a critical 
component in the clinical management of ESRD patients.  
Management of hyperphosphatemia is challenging and a multi-faceted 
approach consisting of dialytic phosphate removal, dietary phosphate 
restrictions and use of phosphate binders [11]. A number of phosphate 
binders, each with its own potential advantages and disadvantages, 
are available for the management of hyperphosphatemia. Calcium-
based phosphate binders are less expensive but their use is confined 
to the development of hypercalcemia. Non-calcium-based phosphate 
binders like sevelamer and lanthanum are expensive, and associated 
with gastrointestinal side effects [11-12]. More recently iron-based 
phosphate binders have also shown to be effective in controlling 
hyperphosphatemia [13].  
In spite of recent advances in the therapeutic management of 
hyperphosphatemia, achievement and maintenance of guideline 
recommendations [11] for serum phosphate remain inadequate. 
Non-compliance with phosphate binders, non-adherence to dietary 
restrictions, inadequate dialysis, refractory disease states and 
financial limitations may account for inadequate control of 
hyperphosphatemia [3, 14-15].  
This study was designed because there is a paucity of data on 
hyperphosphatemia in ESRD patients of the multiethnic population 
of United Arab Emirates (UAE). To our knowledge, no study in UAE 
has yet addressed hyperphosphatemia in ESRD patients on 
hemodialysis. The aim of this study was to investigate the 
prevalence and characteristics of hyperphosphatemia in ESRD 
patients of the multiethnic population of UAE undergoing 
maintenance hemodialysis. 
MATERIALS AND METHODS 
Methods 
Study design and setting 
This study was a prospective observational study involving ESRD 
patients undergoing maintenance hemodialysis at the dialysis unit of 
a secondary care hospital in RAK, UAE.  
Sample selection 
ESRD patients aged more than 18 y, either gender, undergoing 
maintenance hemodialysis for more than six months at the dialysis 
unit of the study site were included in the study. Patients with acute 
kidney injury, undergoing less than thrice weekly hemodialysis and 
who were on hemodialysis for less than six months were not 
included in the study. 
Data collection 
Demographic, clinical and biological data were collected from the 
electronic patient case records and documented in the data collection 
form designed for the study. Demographic and clinical data included age, 
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sex, nationality, height, weight, body mass index (BMI), duration on 
hemodialysis, number of hemodialysis sessions/week, the cause of end-
stage renal disease, type of comorbidities, number of comorbidities and 
medications. Biological data included values of haemoglobin, serum 
creatinine, urea, calcium, phosphate, calcium-phosphate product, 
parathyroid hormone (PTH), alkaline phosphatase (ALP) and Kt/V. 
Serum phosphate was the parameter of interest. A serum phosphate 
level of>1.45 mmol/l was considered hyperphosphatemia as per Kidney 
Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline 
for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic 
Kidney Disease-Mineral and Bone Disorder (CKD-MBD) [11]. All data 
were collected and checked for completeness by the study investigators. 
The patients’ adherence to dietary phosphate restrictions and phosphate 
binders was ascertained by the dialysis unit nursing staff. 
Data analysis 
Statistical analysis of the data was performed using the Statistical 
Package for the Social Sciences (SPSS) version 20.0. Continuous variables 
were expressed as the mean and standard deviation, and categorical 
variables were expressed as percentages. Serum phosphate was the only 
quantitative parameter analyzed as a two-category variable: normal or 
high (threshold 1.45 mmol/l). Patient characteristics were compared as 
per the serum phosphate level, between patients with normal or high 
serum phosphate levels using the Pearson χ2 test for categorical 
variables and ANOVA for continuous variables. Univariate and 
multivariate logistic regression analyses were carried out to identify the 
predictors of hyperphosphatemia. Variables showing the tendency of 
association with hyperphosphatemia (P<0.25) in univariate analysis 
were considered for multivariate logistic regression analysis to identify 
independent predictors of hyperphosphatemia. P<0.05 was considered 
statistically significant. 
Ethics approval 
The study was approved by Ras Al Khaimah (RAK) Medical and 
Health Sciences University Research and Ethics Committee 
(Number: 4-2015-F-P), and RAK Research and Ethics Committee, 
UAE (Number: Sep-2015-1). No formal informed consent was 
required as it was an observational study. 
RESULTS 
Out of the 100 patients undergoing maintenance hemodialysis at the 
study site, 20 patients were not included in the study as they met the 
exclusion criteria. Therefore 80 patients were considered for data 
analysis. The mean age of the patients was 61.1±9.4 y and 57.5 % 
were females. The mean BMI of the study population was 27.5±2.1. 
Thirty-five (43.8%) patients were locals (Emiratis) whereas 45 
(56.2%) were expatriates.  
Among the patients studied, 59 (73.8%) presented with 
hyperphosphatemia and 21 (31.3%) presented with the high calcium-
phosphate product (defined by the mean calcium-phosphate 
product>4.4 mmol2/l2). The study population had mean serum 
phosphate level of 1.73±0.45 mmol/l and mean calcium-phosphate 
product level of 3.7±0.9 mmol2/l2
Table 1 shows the descriptive data of the study population stratified 
by the level of serum phosphate. 
. The mean Kt/V value of the study 
population was 1.28±0.26. Overall, 72 patients (90%) were receiving 
phosphate binders. Out of these 72 patients, 17 (21.3%) were 
receiving sevelamer alone, 14 (17.5%) were receiving calcium 
carbonate alone and 41 (51.2%) were receiving sevelamer as well as 
calcium carbonate.  
  
Table 1: Characteristics of ESRD patients with and without hyperphosphatemia 
Variable N All subjects Serum phosphate (mmol/l) P-value 
≤1.45 (n=21) >1.45 (n=59) 
Age, years (m±SD) 80 61.1±9.4 64.6±10.9 59.8±8.6 0.046 
Gender (%)      
Female  80 57.5 38.1 64.4 0.043 
Male   42.5 61.9 35.6  
Nationality (%) 80    0.021 
Emirati  43.8 66.7 35.6  
Expatriate  56.2 33.3 64.4  
Hemodialysis duration (%) 80    0.059 
≤2 years  68.8 85.7 62.7  
>2 years  31.2 14.3 37.3  
Body mass index, kg/m2 80  (m±SD) 27.5±2.1 26.2±0.8 27.9±2.2 <0.001 
Cause of renal disease (%) 80    0.016 
Hypertensive Nephropathy  33.8 57.2 25.4  
Diabetic Nephropathy  25.0 9.5 30.5  
Hypertensive+Diabetic Nephropathy  28.7 14.3 33.9  
Others  12.5 19.0 10.2  
Number of comorbidities (%) 80    0.011 
One to two comorbidities  51.2 76.2 42.4  
More than two comorbidities  48.8 23.8 57.6  
Laboratory variables (m±SD)      
Hemoglobin, g/dl 80 10.93±1.1 11.6±1.9 10.7±1.1 0.001 
Serum creatinine, mmol/l 80 426.8±157.7 409.9±160.3 432.8±157.8 0.571 
Urea, mmol/l 80 11.3±5.6 10.5±6.8 11.6±5.1 0.434 
Serum calcium, mmol/l 80 2.1±0.2 2.2±0.2 2.1±0.2 0.006 
Calcium x Phosphate, mmol2/l 80 2 3.7±0.9 2.8±0.8 3.9±0.8 <0.001 
Parathyroid hormone, pmol/l 80 64.9±58.6 39.7±13.9 73.9±65.5 0.020 
Alkaline phosphatase, IU/l 80  134.1±137. 6 150.2±157.5 128.4±130.9 0.537 
Medications (%)      
ACEI 80 17.5 23.8 15.3 0.283 
ARB 80 33.8 33.3 33.9 0.593 
CCB 80 82.5 81.0 83.1 0.532 
Diuretics 80 38.8 19.0 45.8 0.026 
Beta Blockers 80 38.8 42.9 37.3 0.422 
Hypoglycemics 80 62.5 52.4 66.1 0.196 
Phosphate binders 80 90.0 61.9 100 <0.001 
ESA 80 86.3 71.4 91.5 0.032 
Iron supplements 80 97.5 95.2 98.3 0.459 
Hypolipedimics 80 77.5 71.4 79.7 0.312 
ACEI angiotensin-converting-enzyme inhibitors, ARB angiotensin receptor blockers, CCB calcium channel blockers, ESA erythropoiesis-stimulating 
agent. Statistically significant values are in bold 
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Patients with hyperphosphatemia were younger (p=0.046), more 
often females (p=0.043) and expatriates (p=0.021), had a higher BMI 
(p<0.001) and presented with a higher number of comorbidities 
(p=0.011) as compared to those with normal serum phosphate 
levels. They were less likely to have hypertensive nephropathy and 
more likely to have diabetic nephropathy as the cause of their renal 
disease. Patients with hyperphosphatemia had lower serum calcium 
(p=0.006) and hemoglobin (p=0.001), and higher calcium-phosphate 
product (p<0.001) and PTH (p=0.020) as compared to those without 
hyperphosphatemia.  
Univariate logistic analysis revealed that hyperphosphatemia was 
inversely correlated with age (OR 0.93, 95% CI 0.87-1.00), 
hemoglobin (OR 0.44, 95% CI 0.26-0.77), serum calcium (OR 0.03, 
95% CI 0.00-0.45) and hypertensive nephropathy as cause of renal 
disease (OR 0.15, 95% CI 0.04-0.50). Hyperphosphatemia was 
positively correlated with female gender (OR 2.94, 95% CI 1.05-
8.23), expatriate status (OR 3.61, 95% CI 1.26-10.36), BMI (OR 1.77, 
95% CI 1.22-2.56), higher number of comorbidities (OR 3.40, 95% CI 
1.15-9.99), calcium-phosphate product (OR 12.36, 95% CI 3.79-
40.32) and PTH (OR 1.04, 95% CI 1.02-1.07) (table 2). 
 
Table 2: Univariate logistic regression analysis demonstrating relationship of hyperphosphatemia with other variables in ESRD patients 
Variable (reference) Odds Ratio 95% CI P-value 
Age, years 0.93 0.87-1.00 0.049 
Gender (Male)    
Female 2.94 1.05-8.23 0.040 
Nationality (Emirati)    
Expatriate 3.61 1.26-10.36 0.017 
Body mass index, k/gm 1.77 1.22-2.56 0.002 
Number of comorbidities (one to two comorbidities)    
More than two comorbidities 3.40 1.15-9.99 0.026 
Cause of renal disease (Diabetic Nephropathy)    
Hypertensive Nephropathy 0.15 0.04-0.50 0.002 
Hemoglobin, g/dl 0.44 0.26-0.77 0.004 
Serum creatinine, mmol/l 1.00 0.99-1.00 0.566 
Urea, mmol/l 1.04 0.94-1.14 0.431 
Serum calcium, mmol/l 0.03 0.00-0.45 0.011 
Calcium x Phosphate, mmol2/l 12.36 2 3.79-40.32 <0.001 
Parathyroid hormone, pmol/l 1.04 1.02-1.07 0.001 
Alkaline phosphatase, IU/l 0.99 0.99-1.00 0.538 
Phosphate binder (Sevelamer)    
Calcium carbonate 0.53 0.09-2.94 0.472 
Sevelamer+Calcium carbonate 1.25 0.27-5.70 0.773 
CI confidence interval. Statistically significant values are in bold,  
 
Multivariate logistic regression model revealed that age (OR 0.84, 
95% CI 0.72-0.97), BMI (OR 2.15, 95% CI 1.25-3.68), hemoglobin 
(OR 0.24, 95% CI 0.06-0.97) and PTH (OR 1.09, 95% CI 1.01-1.17) 
independently correlated with hyperphosphatemia (table 3).
 
Table 3: Multivariate logistic regression analysis of selected variables associated with hyperphosphatemia in ESRD patients 
Variable (reference) Odds ratio 95% CI P-value 
Age, years 0.84 0.72-0.97 0.023 
Gender (Male)    
Female 3.52 0.30-41.41 0.316 
Nationality (Emirati)    
Expatriate 3.75 0.42-33.21 0.234 
Body mass index, kgm 2.15 1.25-3.68 0.005 
Number of comorbidities (one to two comorbidities)    
More than two comorbidities 1.65 0.08-33.68 0.744 
Cause of renal disease (Diabetic Nephropathy)    
Hypertensive Nephropathy 0.31 0.02-4.97 0.408 
Hemoglobin, g/dl 0.24 0.06-0.97 0.045 
Serum calcium, mmol/l 0.046 0.00-7.98 0.242 
Parathyroid hormone, pmol/l 1.09 1.01-1.17 0.030 
CI confidence interval. Statistically significant values are in bold 
 
DISCUSSION 
Hyperphosphatemia is significantly associated with increased 
cardiovascular morbidity and all-cause mortality among ESRD 
patients on maintenance hemodialysis. Hyperphosphatemia was 
present in 73.8% of our patients. The reported prevalence of 
hyperphosphatemia in dialysis patients based on different studies is 
between 50% and 70% [16-19]. Our results are in line with these 
published studies, although there is a slightly higher prevalence of 
hyperphosphatemia in our study population which can be attributed 
to the variability in the age, gender, BMI and ethnic backgrounds 
between our patients and those previously studied. In addition, our 
study also showed that 31.3% of the patients presented with the 
high calcium-phosphate product. This finding is similar to previously 
published studies [16-17, 19]. Studies have demonstrated that both 
hyperphosphatemia and high calcium-phosphate product are 
implicated in cardiovascular events and mortality among dialysis 
patients [5-7, 20].  
Guidelines recommend adequate control of serum phosphate with 
phosphate-restricted diet, oral phosphate binders and dialytic 
phosphate removal in patients with ESRD on dialysis [11]. There are 
no definite recommendations for the use of a specific phosphate 
binder for all the patients because of inconclusive data on their 
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comparative efficacy. Appropriate selection of the phosphate binder 
should be done taking into account CKD stage, the presence of 
different components of CKD–MBD, concomitant drug therapies and 
safety profile of the phosphate binder [11]. In our study, more than 
half of the patients (51.2%) were receiving both sevelamer and 
calcium carbonate, 21.3% and 17.5% were receiving sevelamer 
alone and calcium carbonate alone respectively. Calcium-based 
phosphate binders are associated with hypercalcemia which can 
lead to extra-skeletal calcification and PTH suppression. In relation 
to biochemical endpoints several studies [21-22] reported that both 
sevelamer and calcium-based salts were equally effective as 
phosphate binders.  
In our study hyperphosphatemia was inversely correlated with age, 
hypertensive nephropathy, haemoglobin and serum calcium, and 
positively correlated with female gender, expatriate status, BMI, a 
higher number of comorbidities, calcium-phosphate product and 
PTH by univariate analysis. However, multivariate analysis indicated 
that only age, BMI, haemoglobin and PTH independently correlated 
with hyperphosphatemia.  
The correlation between hyperphosphatemia and lower age has 
been reported by many studies conducted in chronic kidney disease 
as well as dialysis population [6, 20, 23-24]. This can be attributed to 
the reduced dietary phosphate intake and changes in renal 
phosphate handling with age [25]. 
Several studies have reported a correlation between 
hyperphosphatemia and female gender [23, 26-27], a similar finding 
was observed in our study as well. The reasons for this association 
are not clear and may be ascribed to the estrogen-mediated 
regulation of renal phosphate reabsorption [25, 28].  
Hyperphosphatemia and its association with higher BMI have been 
described in dialysis population [5, 23, 29]. The reason can be 
attributed to the fact that the major determinants of both the BMI 
and serum phosphate are the dietary habits and nutritional status.  
The population of UAE is multi-ethnic comprising of Emiratis and 
expatriates from different countries like India, Pakistan, Bangladesh, 
Sri Lanka, Egypt, Iraq, Syria, Iran, etc. The correlation of 
hyperphosphatemia and expatriates may be attributed to external 
factors like their dietary habits consisting of high consumption of 
protein-rich diet and processed foods with high phosphate contents. 
Further studies are warranted to elucidate precise factors for this 
correlation. 
The inverse association of hyperphosphatemia with hypertensive 
nephropathy has been reported by a previous study [23]. The 
mechanisms underlying this association are not known. 
Hyperphosphatemia and its positive association with a higher 
number of comorbidities may be explained by the derangements of 
mineral metabolism in the presence of multiple comorbidities. 
Recent studies have reported the association of hyperphosphatemia 
with low haemoglobin in individuals without kidney disease [30, 
27], in early CKD [27], in ESRD patients [31] and kidney transplant 
recipients [32]. Many mechanisms have been put forward to explain 
this association in CKD and ESRD patients. This relationship may be 
mediated by inhibition of erythropoiesis both by elevated PTH [33] 
and uremic toxins polyamines [32], elevated PTH induced 
breakdown of RBCs [34] and bone marrow fibrosis [34-35].  
As the renal function worsens, mineral metabolism progressive 
deteriorates; hypocalcemia develops as a result of fall in activated 
vitamin D levels increasing PTH, leading to secondary 
hyperparathyroidism [36-37]. This explains the association of 
hyperphosphatemia with low serum calcium and high PTH level.  
The main limitations of our study were that it was an observational, 
single-centre study with a small sample size, which may not be the 
complete representation of the multiethnic population of UAE. 
CONCLUSION 
In conclusion, we report a high prevalence of hyperphosphatemia in 
multiethnic study population undergoing maintenance hemodialysis 
at a secondary care hospital in UAE. We found out that in our study 
population hyperphosphatemia was associated with lower age, 
female gender, expatriate status, higher BMI, lower haemoglobin 
and serum calcium, higher PTH and a higher number of 
comorbidities. Furthermore, our results revealed that only age, 
hemoglobin, BMI and PTH were the independent predictors of 
hyperphosphatemia. 
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